8-K: Checkpoint Therapeutics Secures $12 Million in Direct Offering, Resubmits Key Application

Checkpoint Therapeutics has finalized a $12 million direct offering and resubmitted its biologics license application for cosibelimab to the FDA.

Summary

• Checkpoint Therapeutics has entered into a securities purchase agreement for a registered direct offering with a single healthcare-dedicated institutional investor.
• The offering includes 1,230,000 shares of common stock, pre-funded warrants for up to 4,623,659 shares, and common warrants for up to 5,853,659 shares.
• The offering price is $2.05 per share and associated common warrant, and $2.0499 per pre-funded warrant and associated common warrant.
• The company expects to receive gross proceeds of approximately $12 million from the offering.
• H.C. Wainwright & Co. acted as the exclusive placement agent and will receive a 7% cash fee, $60,000 for non-accountable expenses, $15,950 for clearing fees, and warrants for 351,220 shares.
• Checkpoint Therapeutics also announced the resubmission of its biologics license application (BLA) to the FDA for cosibelimab, a potential treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC).

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. The company has secured funding and resubmitted a key application, but there are risks associated with regulatory approval and dilution.

Positives

• The company successfully raised $12 million through a direct offering, providing additional capital.
• The resubmission of the BLA for cosibelimab indicates progress in the regulatory pathway for this drug.
• The FDA did not raise concerns about the clinical data, safety, or labeling of cosibelimab in the complete response letter.
• The company has reached alignment with the FDA on its BLA resubmission strategy.

Negatives

• The offering involves the issuance of a significant number of new shares and warrants, which could dilute existing shareholders.
• The company is paying a 7% cash fee to the placement agent, plus additional expenses and warrants, which is a significant cost.
• The need to resubmit the BLA for cosibelimab indicates previous issues with the application process.
• The common warrants are exercisable only after stockholder approval, which introduces a potential delay.

Risks

• The company is dependent on the FDA's approval of the resubmitted BLA for cosibelimab.
• There is a risk that the FDA may not accept the resubmitted BLA or may require additional information.
• The company's third-party contract manufacturing organization (CMO) needs to adequately address the issues raised in the complete response letter.
• The company may face challenges in commercializing cosibelimab if approved.
• The company is dependent on the success of its clinical trials and regulatory approvals for its products.
• The company may need to raise additional capital in the future.

Future Outlook

The company intends to use the net proceeds from the offering for working capital and general corporate purposes. The company is also focused on obtaining regulatory approval for cosibelimab and advancing its other pipeline products.

Industry Context

The announcement reflects the ongoing need for capital in the biotechnology sector, particularly for companies in the clinical stage. The resubmission of the BLA for cosibelimab is a key milestone for Checkpoint Therapeutics, as it seeks to bring a new treatment option to market for patients with cSCC. The company is competing with other companies developing immunotherapies for cancer.

Comparison to Industry Standards

• The direct offering is a common method for raising capital in the biotech industry, especially for companies that are not yet profitable.
• The pricing of the offering at $2.05 per share is at-the-market, which is typical for such transactions.
• The use of a placement agent and the associated fees are standard practice in these types of offerings.
• The resubmission of a BLA is not uncommon in the pharmaceutical industry, as companies often need to address issues raised by regulatory agencies.
• The company's focus on developing immunotherapies for cancer aligns with current trends in the oncology field.
• Comparable companies in the immuno-oncology space include companies such as Regeneron, Bristol Myers Squibb, and Merck, all of which have approved PD-1/PD-L1 inhibitors.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares and warrants.
• The company's employees may benefit from the additional funding and progress in product development.
• Patients with cSCC may benefit from the potential approval of cosibelimab.
• The company's creditors may be impacted by the company's financial performance and ability to repay debts.

Next Steps

• The company will close the offering on or about July 3, 2024.
• The company will seek stockholder approval for the issuance of shares upon exercise of the common warrants.
• The company will await the FDA's decision on the resubmitted BLA for cosibelimab.
• The company will continue to develop its other pipeline products.

Key Dates

Keywords

Checkpoint Therapeutics, direct offering, cosibelimab, biologics license application, FDA, cutaneous squamous cell carcinoma, warrants, H.C. Wainwright, capital raise, oncology